Challenges of vaccine development include regulatory, technical, and manufacturing hurdles in translating a vaccine candidate into a commercial product.
Suma Ray, PhD
Advertisement
Suma Ray, PhD, is a process development scientist, viral clearance and cell line development, Global Purification Technologies Group at Sartorius Stedim Biotech
Articles by Suma Ray, PhD
How to implement a risk-based approach to eliminate viruses using orthogonal technologies.
How to implement a risk-based approach to eliminating viruses.
Advertisement
Latest Updated Articles
Key Considerations for Development and Production of Vaccine ProductsPublished: March 2nd 2012 | Updated:
Virus Clearance Strategy Using a Three-Tier Orthogonal Technology PlatformPublished: October 2nd 2009 | Updated:
Viral Clearance Strategy Using a Three-Tier Orthogonal Technology PlatformPublished: September 1st 2008 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
New Cellevate Nanofiber Microcarriers Aim to Transform Vaccine Manufacturing Processes
2
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
3
Everything to Know About Cell and Gene Therapy in 2025
4
In KPMG's CEO Outlook, AI, Regulatory Demands, and Supply Chain Risk Rank High
5
